Screener
Axsome Therapeutics AXSM EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Axsome Therapeutics’s 10-Q, filed August 10, 2026. Open the filing →
- Filed
- Aug 10, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-342360
FAQ
- What is Axsome Therapeutics's EPS (diluted)?
- Axsome Therapeutics (AXSM) reported EPS (diluted) of -$0.99 in Q2 2026.
- How has Axsome Therapeutics's EPS (diluted) changed year-over-year?
- Axsome Therapeutics's EPS (diluted) decreased by 2.1% year-over-year, from -$0.97 to -$0.99.
- What is the long-term trend for Axsome Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Axsome Therapeutics's EPS (diluted) has grown at a 1.5% compound annual growth rate (CAGR), from -$3.47 to -$3.68.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Axsome Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude